Globeimmune, Inc. (OTCMKTS:GBIM) is a clinical‐stage biotechnology company specializing in the development of immunotherapies for cancer and infectious diseases. The company’s research centers on harnessing the body’s immune system to target malignant cells and pathogens through precision‐engineered vaccine and adjuvant platforms. By combining proprietary antigen delivery technologies with immunomodulatory agents, Globeimmune aims to generate durable immune responses against challenging disease targets.
At the core of Globeimmune’s pipeline is a suite of therapeutic candidates designed to address oncogenic drivers and virally induced tumors. Lead programs include GI-4000, a peptide‐based vaccine targeting RAS mutations commonly found in pancreatic and colorectal cancers, and GI-6207, an antigen‐directed immunotherapy for HPV‐associated head and neck malignancies. Additionally, the company is advancing immunomodulatory adjuvants and combination regimens intended to amplify vaccine efficacy and broaden the spectrum of responsive patient populations.
Founded in 1998 and headquartered in Carlsbad, California, Globeimmune has progressed its clinical candidates through multiple Phase 1 and 2 studies in the United States and Europe. The company maintains research collaborations with academic and medical centers to optimize its delivery systems and to explore novel indications in oncology and allergy. Through strategic licensing partnerships, Globeimmune seeks to extend its geographic reach into key markets in Asia and North America.
Globeimmune is led by an experienced management team and board of directors whose expertise spans immunology, oncology drug development, regulatory affairs and commercial strategy. The company’s leadership is focused on advancing late‐stage clinical programs, securing strategic alliances and positioning its pipeline for potential partnership or commercialization opportunities in global markets.
AI Generated. May Contain Errors.
